MA23533A1 - Formes posologiques d'azithromycine - Google Patents

Formes posologiques d'azithromycine

Info

Publication number
MA23533A1
MA23533A1 MA23865A MA23865A MA23533A1 MA 23533 A1 MA23533 A1 MA 23533A1 MA 23865 A MA23865 A MA 23865A MA 23865 A MA23865 A MA 23865A MA 23533 A1 MA23533 A1 MA 23533A1
Authority
MA
Morocco
Prior art keywords
azithromycin
dosage forms
dosing
disintrigrating
eaten
Prior art date
Application number
MA23865A
Other languages
English (en)
Inventor
H Foulds George
J Curatolo William
L Friedman Hylar
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22883977&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA23533(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of MA23533A1 publication Critical patent/MA23533A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
MA23865A 1994-04-29 1995-04-26 Formes posologiques d'azithromycine MA23533A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/235,069 US5605889A (en) 1994-04-29 1994-04-29 Method of administering azithromycin

Publications (1)

Publication Number Publication Date
MA23533A1 true MA23533A1 (fr) 1995-12-31

Family

ID=22883977

Family Applications (1)

Application Number Title Priority Date Filing Date
MA23865A MA23533A1 (fr) 1994-04-29 1995-04-26 Formes posologiques d'azithromycine

Country Status (31)

Country Link
US (2) US5605889A (fr)
EP (1) EP0679400B1 (fr)
JP (3) JPH07300420A (fr)
KR (1) KR100354310B1 (fr)
CN (1) CN1088362C (fr)
AP (1) AP566A (fr)
AT (1) ATE183395T1 (fr)
AU (1) AU709328B2 (fr)
CA (1) CA2148071C (fr)
CO (1) CO4560547A1 (fr)
DE (1) DE69511451T2 (fr)
DK (1) DK0679400T3 (fr)
DZ (1) DZ1877A1 (fr)
ES (1) ES2136247T3 (fr)
FI (1) FI952060A (fr)
GR (1) GR3031290T3 (fr)
HU (1) HUT75244A (fr)
IL (1) IL113437A (fr)
LV (1) LV10918B (fr)
MA (1) MA23533A1 (fr)
NO (1) NO314386B1 (fr)
NZ (1) NZ548384A (fr)
OA (1) OA10151A (fr)
RU (1) RU2128998C1 (fr)
SI (1) SI0679400T1 (fr)
TN (1) TNSN95046A1 (fr)
TW (1) TW499311B (fr)
UA (1) UA34464C2 (fr)
UY (1) UY23935A1 (fr)
YU (1) YU49483B (fr)
ZA (1) ZA953439B (fr)

Families Citing this family (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2163504T5 (es) † 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.
ES2079327B1 (es) * 1994-12-13 1996-08-01 Lilly Sa Formulaciones farmaceuticas de cefaclor.
PT801559E (pt) * 1995-02-08 2002-09-30 Yamanouchi Europ Bv Processo para a preparacao de formas de dosagem oral contendo um antibiotico de beta-lactama
US20060003447A1 (en) * 2003-12-30 2006-01-05 Richard Fike Dry powder cells and cell culture reagents and methods of production thereof
US6383810B2 (en) * 1997-02-14 2002-05-07 Invitrogen Corporation Dry powder cells and cell culture reagents and methods of production thereof
US20030212123A1 (en) * 1997-05-05 2003-11-13 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
US6146655A (en) * 1997-08-29 2000-11-14 Softy-Flex Inc. Flexible intra-oral bandage and drug delivery system
US6129932A (en) * 1997-09-05 2000-10-10 Merck & Co., Inc. Compositions for inhibiting platelet aggregation
US6861411B1 (en) * 1997-12-02 2005-03-01 Pfizer, Inc. Method of treating eye infections with azithromycin
US5955107A (en) * 1997-12-12 1999-09-21 Fmc Corporation Pharmaceutical suspension tablet compositions
US5916594A (en) * 1997-12-22 1999-06-29 Schering Corporation Process of making solid ribavirin dosage forms
EP1321147A1 (fr) * 1997-12-22 2003-06-25 Schering Corporation Forme posologique solide comprenant de la ribavirine, pour administration par voie orale, et son procédé de fabrication
US5914128A (en) * 1997-12-22 1999-06-22 Schering Corporation Orally administrable solid dosage form
US6239112B1 (en) * 1998-07-09 2001-05-29 Merial, Inc. Water miscible macrolide solutions
FR2793690B1 (fr) * 1999-03-30 2003-01-03 Cll Pharma Formulations pharmaceutiques en macrolides seuls ou associes a d'autres principes actifs et leur utilisation en therapeutique
US7056893B2 (en) * 1999-03-31 2006-06-06 Insite Vision, Inc. Topical treatment for prevention of ocular infections
CZ300551B6 (cs) * 1999-03-31 2009-06-17 Janssen Pharmaceutica N. V. Predželatinovaný škrob v rízene se uvolnující formulaci
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
IL141438A0 (en) * 2000-02-23 2002-03-10 Pfizer Prod Inc Method of increasing the bioavailability and tissue penetration of azithromycin
EP1304326B1 (fr) * 2000-07-25 2006-03-15 Laboratorio Silanes, S.A. de C.V. Procede permettant de preparer en une seule etape de la 7,16-dioxa-2-aza-10-o-cladinosyl-12-o-desosaminyl-4,5-dihydroxy-6-ethyl-3,5,9,11,13,15-hexamethylbicyclo 11.2.1]hexa-deca-1(2)-en-8-one et permettant d'obtenir une nouvelle forme de 9-desoxo-9a-aza-9a-methyl-9a-homoerythromycine a
ATE306491T1 (de) 2000-08-23 2005-10-15 Wockhardt Ltd Verfahren zur herstellung von wasserfreiem azithromycin
EP1339829B1 (fr) * 2000-11-06 2018-10-24 Life Technologies Corporation Milieu de culture cellulaire sec, et methodes de production correspondantes
JP3836790B2 (ja) * 2000-11-15 2006-10-25 昌雄 菅又 子宮内膜症の予防又は治療薬
HRP20010301A2 (en) * 2001-04-27 2001-12-31 Pliva D D New therapeutic indication for azithromycin in the treatment of non-infective inflammatory diseases
YU91603A (sh) * 2001-05-22 2006-08-17 Pfizer Products Inc. Kristalni oblici azitromicina
EP1671979B1 (fr) 2001-05-22 2008-08-13 Pfizer Products Inc. Nouvelle forme cristalline de l'azithromycine
KR20040032942A (ko) * 2001-08-21 2004-04-17 화이자 프로덕츠 인코포레이티드 호흡기 감염증을 치료하기 위한 일회분량의 아지트로마이신
GB0123400D0 (en) 2001-09-28 2001-11-21 Novartis Ag Organic compounds
AU2006218279B2 (en) * 2001-09-28 2009-12-10 Novartis Ag Pharmaceutical compositions comprising colloidal silicon dioxide
EP1541134A3 (fr) * 2001-10-18 2007-06-06 Teva Pharmaceutical Industries Limited Compositions stabilisées de azithromycin
US20080149521A9 (en) * 2001-10-18 2008-06-26 Michael Pesachovich Methods of stabilizing azithromycin
DK1446010T3 (da) * 2001-10-18 2009-06-22 Teva Pharma Stabiliseret azithromycin-sammensætning
BR0215175A (pt) * 2001-12-21 2004-12-28 Pfizer Prod Inc Métodos para a granulação úmida de azitromicina
CA2469246A1 (fr) * 2001-12-21 2003-07-03 Pfizer Products Inc. Formulations d'azithromycine directement compressibles
JP2006501137A (ja) * 2002-01-16 2006-01-12 ペプジェン コーポレイション インターフェロン−τの経口投与
CA2474809A1 (fr) * 2002-02-01 2003-08-07 Pfizer Products Inc. Preparation d'azithromycine en granulat sec
JP2005527508A (ja) * 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド 経口デリバリー用急速溶融多粒子製剤
US7101576B2 (en) * 2002-04-12 2006-09-05 Elan Pharma International Limited Nanoparticulate megestrol formulations
US20040105889A1 (en) * 2002-12-03 2004-06-03 Elan Pharma International Limited Low viscosity liquid dosage forms
US9101540B2 (en) * 2002-04-12 2015-08-11 Alkermes Pharma Ireland Limited Nanoparticulate megestrol formulations
US20100226989A1 (en) * 2002-04-12 2010-09-09 Elan Pharma International, Limited Nanoparticulate megestrol formulations
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
BG748Y1 (bg) * 2002-07-02 2005-06-30 "BALKANFARMA-RAZGRAD" AD A{ô­{òM{}ö{ }{GC}{D A{DAAAAAAAAAAAAAAAAAAAAAAAAAA ЛЕКАРСТВЕНАБФОРМАБББББББББББББББББББББББББББББББББФЕДЙГБФЕХгЦдв@ЖЦЩФ@@@@@@@@@@@
WO2004074132A1 (fr) * 2003-02-19 2004-09-02 Teva Pharmaceutical Industries Ltd. Procede servant a stabiliser azithromycine pendant sa conservation par emballage dans un conteneur impermeable au gaz
WO2004100880A2 (fr) * 2003-05-06 2004-11-25 Nirmal Mulye Formulation a liberation controlee de derives d'erythromycine
US20050013835A1 (en) * 2003-07-15 2005-01-20 Pfizer Inc. Stable non-dihydrate azithromycin oral suspensions
ATE421882T1 (de) * 2003-07-24 2009-02-15 Pliva Hrvatska D O O Schnellösliches azithromycin in einzeldosisform
AR045142A1 (es) 2003-07-30 2005-10-19 Novartis Ag Composicion veterinaria masticable ductil de buen sabor
WO2005021056A1 (fr) * 2003-08-21 2005-03-10 Cns, Inc. Systeme de distribution de materiau effervescent
BRPI0416535A (pt) * 2003-12-04 2007-01-09 Pfizer Prod Inc processo de congelamento por vaporização empregando um extrusor para preparar composições de azitromicina de multiparticulado contendo preferivelmente um poloxámero e um glicerìdeo
BRPI0417338A (pt) * 2003-12-04 2007-04-17 Pfizer Prod Inc formas de dosagem de azitromicina multiparticulada por processos a base de lìquido
SI1691787T1 (sl) * 2003-12-04 2008-10-31 Pfizer Prod Inc Postopek za pripravo farmacevtskih produktov iz več delcev
JP2007513147A (ja) * 2003-12-04 2007-05-24 ファイザー・プロダクツ・インク 押し出し機を使用して、好ましくはポロキサマーとグリセリドを含有する多粒子結晶性医薬組成物を製造するための噴霧凝結方法
WO2005053652A1 (fr) 2003-12-04 2005-06-16 Pfizer Products Inc. Compositions medicamenteuses cristallines multiparticulaires contenant un poloxamere et un glyceride
US6984403B2 (en) * 2003-12-04 2006-01-10 Pfizer Inc. Azithromycin dosage forms with reduced side effects
WO2005053639A2 (fr) * 2003-12-04 2005-06-16 Pfizer Products Inc. Formes multiparticulaires a liberation controlee produites avec des optimiseurs de dissolution
EP1691786A1 (fr) * 2003-12-04 2006-08-23 Pfizer Products Inc. Compositions multiparticulaires a stabilite amelioree
CN1697648B (zh) * 2003-12-04 2010-06-23 辉瑞产品公司 减少了副作用的阿奇霉素剂型
US20050131079A1 (en) * 2003-12-10 2005-06-16 Pujara Chetan P. Cefdinir oral suspension
JP2007517055A (ja) * 2003-12-30 2007-06-28 スリーエム イノベイティブ プロパティズ カンパニー 免疫応答の増強
US7468428B2 (en) * 2004-03-17 2008-12-23 App Pharmaceuticals, Llc Lyophilized azithromycin formulation
US20060116336A1 (en) * 2004-03-17 2006-06-01 American Pharmaceutical Partners, Inc. Lyophilized azithromycin formulation
JP4713104B2 (ja) * 2004-08-04 2011-06-29 ファイザー株式会社 アジスロマイシン類を有効成分とする苦味が抑制された安定な組成物
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
US20060182806A1 (en) * 2004-11-08 2006-08-17 Mintong Guo Extended-release propranolol composition
DE05815688T1 (de) * 2005-01-27 2008-06-26 Alembic Ltd. Levetiracetam-formulierung mit verlängerter freisetzung
CA2600623A1 (fr) * 2005-03-07 2006-09-14 Teva Pharmaceutical Industries Ltd. Poudre d'azithromycine pour compositions de suspension orale
US20060198895A1 (en) * 2005-03-07 2006-09-07 Kotliar Eleonora M Azithromycin powder for oral suspension compositions
ES2535478T3 (es) 2005-05-26 2015-05-12 Sumitomo Dainippon Pharma Co., Ltd. Composición farmacéutica
US20080274178A1 (en) * 2005-08-10 2008-11-06 Shionogi & Co., Ltd. Orally Disintegrating Tablet
US20070191271A1 (en) * 2006-02-10 2007-08-16 Dow Pharmaceutical Sciences Method for stabilizing polypeptides lacking methionine
US8187659B2 (en) 2006-05-02 2012-05-29 Jerry Robertson Real Estate Llc Solid medicament dosage form consumption aid
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
US8124123B2 (en) * 2007-09-05 2012-02-28 Dow Pharmaceutical Sciences, Inc. Controlled release azithromycin solid dosages forms
JP5849947B2 (ja) 2010-03-29 2016-02-03 アステラス製薬株式会社 放出制御医薬組成物
WO2013088274A1 (fr) 2011-12-14 2013-06-20 Wockhardt Limited Composition d'azithromycine amorphe anhydre dépourvue de dihydrate d'azithromycine
AP2014007874A0 (en) 2012-02-06 2014-08-31 Merial Ltd Parasiticidal oral veterinary compositions comprising systemetically- acting active agents, methods and uses thereof
CA2864322C (fr) 2012-02-28 2016-08-09 Seoul Pharma. Co., Ltd. Film a haute teneur et a dissolution rapide a gout amer masque comprenant du sildenafil comme principe actif
RU2498805C1 (ru) * 2012-07-23 2013-11-20 Открытое акционерное общество "Биосинтез" Твердая лекарственная форма азитромицина
CN104177457A (zh) * 2013-05-23 2014-12-03 长春海悦药业有限公司 一种阿奇霉素药物原料及其制剂和用途
US20150132382A1 (en) * 2013-11-11 2015-05-14 Forest Laboratories Holdings Ltd. Compositions and methods of treatment comprising fosfomycin disodium
RU2649834C1 (ru) * 2016-07-06 2018-04-04 Фармалидер С.А. Фармацевтическая композиция силденафила цитрата в форме суспензии для перорального применения

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
YU43006B (en) * 1981-03-06 1989-02-28 Pliva Pharm & Chem Works Process for preparing n-methyl-11-aza-10-deoxo-10-dihydro erythromycin and derivatives thereof
US4382085A (en) * 1982-03-01 1983-05-03 Pfizer Inc. 4"-Epi erythromycin A and derivatives thereof as useful antibacterial agents
US4474768A (en) * 1982-07-19 1984-10-02 Pfizer Inc. N-Methyl 11-aza-10-deoxo-10-dihydro-erytromycin A, intermediates therefor
WO1989000576A1 (fr) 1987-07-09 1989-01-26 Pfizer Inc. Dihydrate d'azithromycine
WO1989002271A1 (fr) * 1987-09-10 1989-03-23 Pfizer Azithromycine et derives utilises comme agents anti-protozoaires
SI9011409A (en) * 1990-07-18 1995-10-31 Pliva Pharm & Chem Works O-methyl azitromycin derivates, methods and intermediates for their preparation and methods for preparation of pharmaceuticals products which comprise them
EP0553353A1 (fr) * 1990-10-15 1993-08-04 Taisho Pharmaceutical Co. Ltd Erythromycine modifiee en 2' ou derive de cette substance
TW271400B (fr) 1992-07-30 1996-03-01 Pfizer
AU7957994A (en) 1993-10-01 1995-05-01 Procter & Gamble Company, The Use of azithromycin for the treatment of adult periodontitis and topical compositions for this use
ES2163504T5 (es) 1994-05-06 2008-05-16 Pfizer Inc. Formas de dosificacion de liberacion controlada de azitromicina.

Also Published As

Publication number Publication date
LV10918B (en) 1996-06-20
AP9500728A0 (en) 1995-04-30
ES2136247T3 (es) 1999-11-16
FI952060A0 (fi) 1995-04-28
UA34464C2 (uk) 2001-03-15
EP0679400B1 (fr) 1999-08-18
NZ548384A (en) 2008-04-30
IL113437A0 (en) 1995-07-31
DE69511451T2 (de) 1999-12-09
EP0679400A1 (fr) 1995-11-02
JP2008231120A (ja) 2008-10-02
ZA953439B (en) 1996-10-28
NO951630D0 (no) 1995-04-28
US5605889A (en) 1997-02-25
LV10918A (lv) 1995-12-20
NO951630L (no) 1995-10-30
CA2148071A1 (fr) 1995-10-30
DE69511451D1 (de) 1999-09-23
ATE183395T1 (de) 1999-09-15
RU2128998C1 (ru) 1999-04-20
AP566A (en) 1996-11-22
UY23935A1 (es) 1995-09-12
JP2005015466A (ja) 2005-01-20
KR100354310B1 (ko) 2002-12-26
TW499311B (en) 2002-08-21
YU49483B (sh) 2006-08-17
NO314386B1 (no) 2003-03-17
AU1771195A (en) 1995-11-09
JPH07300420A (ja) 1995-11-14
CN1088362C (zh) 2002-07-31
CN1114879A (zh) 1996-01-17
CA2148071C (fr) 2000-10-17
CO4560547A1 (es) 1998-02-10
OA10151A (en) 1996-12-18
YU27195A (sh) 1999-03-04
RU95106639A (ru) 1997-01-20
HUT75244A (en) 1997-05-28
USRE39149E1 (en) 2006-06-27
AU709328B2 (en) 1999-08-26
DZ1877A1 (fr) 2002-02-17
IL113437A (en) 2001-04-30
HU9501206D0 (en) 1995-06-28
FI952060A (fi) 1995-10-30
GR3031290T3 (en) 1999-12-31
SI0679400T1 (en) 1999-10-31
KR950028764A (ko) 1995-11-22
DK0679400T3 (da) 1999-12-06
TNSN95046A1 (fr) 1996-02-06

Similar Documents

Publication Publication Date Title
MA23533A1 (fr) Formes posologiques d'azithromycine
FI880425A (fi) Antibakteriellinen plakkia ja hammaskiveä estävä oraalinen koostumus
ATE114472T1 (de) System des typs ''einmal täglich'' zur gepulsten minocyclinabgabe.
DE60031396D1 (de) Zubereitung zur behandlung von einer neurologischen erkrankung
DE68923819T2 (de) Verwendung von gamma-Hydroxy-Buttersäuresalzen zur Herstellung von pharmazeutischen Zusammensetzungen zur Verwendung bei der Behandlung von Alkoholismus und die hergestellten Zusammensetzungen.
DK0430474T3 (da) Præparater med vedvarende frigivelse til behandling af periodontal sygdom
DE69310443T2 (de) Präparat zur oralen Hygiene
DK0429225T3 (da) Sammensætninger med vedvarende frigørelse til behandling af periodontal sygdom
SE9201930D0 (sv) Gastric antibacterial treatment
DE58906881D1 (de) Gerät zur Zahnbehandlung.
DE69108143D1 (de) Rotogranulate und geschmacksabdeckende Überzüge zur Herstellung pharmazeutischer Kautabletten.
DE29517758U1 (de) Vorrichtung zur Mundpflege
ITRM990339A0 (it) Derivati di principi attivi ad attivita' terapeutica e/o nutrizionalee composizioni atte alla somministrazione orale contenenti tali deriva
DK99993D0 (da) Treatment and prophylaxis of diseases caused by parasites or bacteria
DE69519040T2 (de) Zusammensetzung zur hygiene,prophylaxe und behandlung der mundhöhle
ATE148611T1 (de) ''pour-on''-formulierungen zur bekämpfung von internen und externen parasiten bei homoöthermen tieren
NO970185D0 (no) Anvendelse av (S)-adenosyl-L-metionin (SAMe) og dets fysiologisk kompatible salter for behandling av reperfusjonsskade utlöst av temporær-fokal-ischemi
PT84996A (de) Pharmazeutische zubereitung zur behandlung bakterieller infektionen
FI953622A (fi) Ifenprodiilin ja sen diastereoisomeerien käyttö lääkeaineiden valmistukseen, jotka lääkeaineet ovat käyttökelpoisia perifeeristen neuropatiatilojen ja keskushermoston degeneratiivisten sairauksien hoitoon
DE69207898T2 (de) Wirkstoff zur hautbehandlung bei tieren
ATE49101T1 (de) Zusammensetzungen zur desinfektion und zur sterilisation.
FR2708202B1 (fr) Implant biocompatible pour l'expression chez l'homme ou chez l'animal de substances déterminées.
DE9311733U1 (de) Kugelstopfer zur Zahnbehandlung
DE9307108U1 (de) Vorrichtung zur Behandlung von Zahnfehlstellungen
IT8848093A0 (it) Composizioni atte ad aumentare la crescita di animali e composti in esse contenuti